KCTD9

Across TCGA pan-cancer cohorts, KCTD9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KCTD9 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher KCTD9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KCTD9 expression acts as an unfavorable survival marker.

ACC, ESCA, and UCEC are the cancer types where KCTD9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
ESCA	OS	Median	All	0.147	0.700	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

KCTD9–ACC (OS)

Open the ACC breakdown →